Profound Medical Corp. announced that its TULSA Procedure will be featured in multiple presentations at the 2026 Society of Interventional Radiology Annual Scientific Meeting, highlighting clinical data and real-world physician experience.
Key takeaways
The TULSA Procedure will be presented at the SIR 2026 meeting from April 11-15 in Toronto, ON.
Five oral presentations on April 12 will cover topics including treatment for MRI-visible prostate cancer, recurrent cancer, and outcomes from the CAPTAIN trial.
Two additional presentations on April 13 will be part of a categorical course titled 'Prostate Interventions: TULSA and Beyond'.
CEO Arun Menawat stated that awareness of the TULSA Procedure's clinical profile is growing and highlighted the presentation of CAPTAIN trial data.
The TULSA Procedure uses robotically controlled directional ultrasound with real-time MRI thermography to treat prostate cancer and BPH with minimal side effects.